Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.

2022 Startups to Watch
stats here
Related Posts on Startland News
Inside KC’s SubTropolis: How Missouri businesses are looking below the surface for new opportunities
Editor’s note: This story was originally published by Missouri Business Alert, a member of the Kansas City Media Collective, which also includes Startland News, KCUR 89.3, American Public Square, Kansas City PBS/Flatland, and The Kansas City Beacon. Click here to read the original story. Visitors driving into SubTropolis on a recent morning were immediately greeted by rows…
Missouri to create ‘Office of Entrepreneurship,’ prioritize access for emerging ventures
Newly signed legislation — part of a nationwide Right to Start initiative with roots in Kansas City — is expected to boost starters across Missouri, advocates said this week, and reflects broad public and bipartisan support for eliminating barriers for new entrepreneurs and overlooked business owners. “Advancing entrepreneurship will energize the Missouri economy,” said Missouri…
Just funded: Meet the newest Digital Sandbox KC startups (and see what they’re building now)
Digital Sandbox KC this week announced five new startups joining its program that will receive crucial support, mentorship and up to $20,000 in project funding to accelerate their innovative projects. “We are delighted to bring these cutting-edge startups into the Sandbox, connecting them with the necessary support and resources to advance their innovative projects,” said…
Matt Watson scales third startup to exit; shifting full capacity to his tech services company
At Capacity is returning to the company where it all began; the SaaS platform recently sold to CAMP Digital, co-founder and serial entrepreneur Matt Watson confirmed. Details of the sale were not disclosed, but the exit comes just 16 months after Watson and Meg Stapleton launched At Capacity. Click here to read more about the…

